Please use this identifier to cite or link to this item:
Title: Scleromyxedema treatment: a systematic review and update
Authors: Haber, Roger
Bachour, Julien
El Gemayel, Maria
Affiliations: Faculty of Medicine 
Issue Date: 2020
Publisher: Wiley Online Library
Part of: International Journal of Dermatology
Volume: 59
Issue: 10
Start page: 1191
End page: 1201
Scleromyxedema is a chronic disease with high morbidity and mortality and no definitive therapeutic guidelines.

To review all available data on the efficacy and the safety of the available treatments of scleromyxedema and suggest a possible therapeutic approach.

Evidence Review
We performed a systematic literature review in Pubmed/Medline, Embase, and Cochrane collaboration databases, searching for all articles since 1990 on the treatments of scleromyxedema, with no limits on participant age, gender, or nationality.

Ninety-seven studies were included in this systematic review, of which one prospective, two retrospective, 70 case reports/case series, and 24 letters/correspondence/clinical image. Intravenous immunoglobulin (IVIG) was the most used first-line therapy based on its efficacy and its generally well-tolerated nature; most patients require continued treatment to remain in remission. Thalidomide and systemic glucocorticoids were mostly considered as second-line therapies and were given alone or in association with IVIG. Patients with severe or refractory disease were treated with autologous bone marrow transplantation, melphalan, or bortezomib with dexamethasone.

Conclusions and Relevance
Consideration of patient comorbidities, disease distribution, clinician experience, and treatment accessibility is mandatory in every therapeutic approach of scleromyxedema.
ISSN: 00119059
DOI: 10.1111/ijd.14888
Ezproxy URL: Link to full text
Type: Journal Article
Appears in Collections:Faculty of Medicine

Show full item record


checked on Jul 2, 2022

Record view(s)

checked on Jul 2, 2022

Google ScholarTM


Dimensions Altmetric

Dimensions Altmetric

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.